NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain…
Forecast
Consensus Buy from 15 analysts. Average price target $26.00, +92.5% versus the current price. Low $20.00. High $32.00.
Analysts have an average 12-month price target of $26.00 for Novocure (NVCR), 97.0% above the current price of $13.20. Of 15 analysts covering the stock, 9 rate it Buy or Strong Buy, 5 Hold, and 1 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
NVCR price target
12-month price target
Low
$20.00
Average
$26.00
High
$32.00
The average is 97.0% above the current price of $13.20.
Is Novocure a buy or sell?
Of 15 analysts, 9 rate Novocure Buy or Strong Buy, 5 Hold, and 1 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
The Stocklytics Score, when it is published for NVCR, averages value, quality, and growth on a 0–100 scale. It is not a price target. Fair value is a separate estimate on the fair value tab.
NVCR forecast FAQs
What is the NVCR price target?
$26.00 average, with a published range of $20.00 to $32.00.
Is Novocure a buy or sell?
The consensus is Buy from 15 analysts. This is not a recommendation.
What is the Novocure stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -1.24. The average revenue estimate is $726.11 million.
What will NVCR be worth in 2030?
No reliable forecast exists that far out.
When is Novocure's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.